Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.70 |
| ▸ | TACR3 | P29371 | 2/20 | 0.66 |
| ▸ | TACR2 | P21452 | 1/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | FPR1 | P21462 | 1/20 | 0.51 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8350518 | 1.00 | TACR1 (0.70) | TACR1TACR3TACR2NR3C1CYP3A4 | |
| SCHEMBL7026820 | 1.00 | TACR1 (0.70) | TACR1TACR3TACR2NR3C1CYP3A4 | |
| SCHEMBL8353379 | 0.96 | TACR1 (0.66) | TACR1TACR3TACR2NR3C1CYP3A4 | |
| SCHEMBL8353376 | 0.96 | TACR1 (0.66) | TACR1TACR3TACR2NR3C1CYP3A4 | |
| SCHEMBL7022339 | 0.94 | TACR1 (0.76) | TACR1TACR3TACR2 | |
| SCHEMBL264224 | 0.94 | TACR1 (0.76) | TACR1TACR3TACR2 | |
| SCHEMBL264225 | 0.94 | TACR1 (0.76) | TACR1TACR3TACR2 | |
| SCHEMBL265029 | 0.90 | TACR1 (0.59) | TACR1TACR3TACR2NR3C1CYP3A4 | |
| SCHEMBL265028 | 0.90 | TACR1 (0.59) | TACR1TACR3TACR2NR3C1CYP3A4 | |
| SCHEMBL8151210 | 0.86 | TACR1 (0.53) | TACR1TACR3TACR2NR3C1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO., INC. | 2002-01-03 | — | — | US | claimed |
| US-6048859-A | ANTIEMETIC AGENT | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | claimed |
| EP-0577394-B1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1999-11-10 | — | — | EP | claimed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | claimed |
| WO-1995023798-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-08 | — | — | WO | claimed |
| WO-1994000440-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-01-06 | — | — | WO | claimed |
| EP-0577394-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | claimed |
| WO-2009116081-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | MSN LABORATORIES LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-6638930-B2 | Antiinflammatory agents, analgesics, antiasthmatics, antiemitics and calcium channel blockers for angina, hypertension or ischemia | MERCK & CO. INC. | 2003-10-28 | — | — | US | disclosed |
| EP-0748320-B1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO., INC. | 2002-01-03 | — | — | US | disclosed |
| US-6235735-B1 | AFTERTREATMENT OF RADIATION THERAPY | MERCK & CO., INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0734381-B1 | MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| EP-0734381-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5512570-A | Treatment of emesis with morpholine tachykinin receptor antagonists | MERCK & CO., INC. (US) | 1996-04-30 | — | — | US | disclosed |
| WO-1995023798-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995016679-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | disclosed |
| WO-1994000440-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0577394-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | TRPM7, TRPM2, TRPM5 | TACR1 23/4885TACR3 46/4885TACR2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.